

Valanafusp alfa

Cat. No.:	HY-P99530
CAS No.:	1815583-32-4
Target:	Insulin Receptor
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Valanafusp alfa (AGT-181) is a brain penetrating recombinant fusion protein of a chimeric monoclonal antibody against the human insulin receptor (HIR) and human iduronidase (IDUA). Valanafusp alfa can be used for the research of Mucopolysaccharidosis type I (MPS I) [1].
In Vitro	Valanafusp alfa (HIRMAb-IDUA) binds to the HIR extracellular domain (ECD) with an EC ₅₀ of 0.93±0.07 nM[2]. Valanafusp alfa (HIRMAb-IDUA) (0.3 µg/mL; 48 h) reduces glycosaminoglycan accumulation in Hurler fibroblasts by 70% as compared to healthy fibroblasts[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Chronic dosing of Valanafusp alfa (AGT-181) (0.2-20 mg/kg; IV) has an excellent safety profile at all doses with no clinical, histologic, or laboratory findings, and no effect on glycemic control in plasma or cerebrospinal fluid[1]. Valanafusp alfa (AGT-181) (0.2-20 mg/kg; IV) is stable, and shows rapid clearance and the high systemic volume of distribution in Rhesus monkeys[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Boado RJ, et al. AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J Biotechnol. 2009 Oct 26;144(2):135-41.

[2]. Boado RJ, et al. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng. 2008 Feb 1;99(2):475-84.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA